CKD Bio Corp. (063160.KS)
KRW 22650.0
(-1.52%)
KRW 22650.0
(-1.52%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 69.43 Billion KRW | -15.23% |
| 2022 | 81.91 Billion KRW | -8.32% |
| 2021 | 89.34 Billion KRW | 49.21% |
| 2020 | 59.88 Billion KRW | 195.87% |
| 2019 | 20.23 Billion KRW | 884.21% |
| 2018 | 2.05 Billion KRW | 1723.05% |
| 2017 | 112.8 Million KRW | -33.33% |
| 2016 | 169.2 Million KRW | -25.0% |
| 2015 | 225.6 Million KRW | -20.0% |
| 2014 | 282 Million KRW | -91.83% |
| 2013 | 3.45 Billion KRW | -38.18% |
| 2012 | 5.58 Billion KRW | -27.63% |
| 2011 | 7.71 Billion KRW | 594.71% |
| 2010 | 1.11 Billion KRW | -46.39% |
| 2009 | 2.07 Billion KRW | 267.43% |
| 2008 | 564 Million KRW | 0.0% |
| 2007 | - KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 64.04 Billion KRW | -4.11% |
| 2024 Q1 | 66.78 Billion KRW | -3.81% |
| 2023 Q2 | 65.25 Billion KRW | -3.95% |
| 2023 Q3 | 100 Billion KRW | 53.25% |
| 2023 Q4 | 69.43 Billion KRW | -30.57% |
| 2023 FY | 69.43 Billion KRW | -15.23% |
| 2023 Q1 | 67.94 Billion KRW | -17.05% |
| 2022 Q3 | 86.43 Billion KRW | 0.25% |
| 2022 Q2 | 86.21 Billion KRW | -1.13% |
| 2022 FY | 81.91 Billion KRW | -8.32% |
| 2022 Q1 | 87.2 Billion KRW | -2.39% |
| 2022 Q4 | 81.91 Billion KRW | -5.24% |
| 2021 FY | 89.34 Billion KRW | 49.21% |
| 2021 Q2 | 69.6 Billion KRW | -1.33% |
| 2021 Q1 | 70.53 Billion KRW | 17.79% |
| 2021 Q4 | 89.34 Billion KRW | 30.1% |
| 2021 Q3 | 68.67 Billion KRW | -1.33% |
| 2020 Q4 | 59.88 Billion KRW | 22.15% |
| 2020 Q1 | 36.37 Billion KRW | 79.74% |
| 2020 Q2 | 43.72 Billion KRW | 20.21% |
| 2020 Q3 | 49.02 Billion KRW | 12.11% |
| 2020 FY | 59.88 Billion KRW | 195.87% |
| 2019 Q4 | 20.23 Billion KRW | 23.97% |
| 2019 FY | 20.23 Billion KRW | 884.21% |
| 2019 Q1 | 9.58 Billion KRW | 366.19% |
| 2019 Q2 | 11.51 Billion KRW | 20.08% |
| 2019 Q3 | 16.32 Billion KRW | 41.82% |
| 2018 FY | 2.05 Billion KRW | 1723.05% |
| 2018 Q4 | 2.05 Billion KRW | 3546.1% |
| 2018 Q3 | 56.4 Million KRW | 0.0% |
| 2018 Q2 | 56.4 Million KRW | -50.0% |
| 2018 Q1 | 112.8 Million KRW | 0.0% |
| 2017 Q4 | 112.8 Million KRW | 0.0% |
| 2017 FY | 112.8 Million KRW | -33.33% |
| 2017 Q3 | 112.8 Million KRW | 0.0% |
| 2017 Q2 | 112.8 Million KRW | -33.33% |
| 2017 Q1 | 169.2 Million KRW | 0.0% |
| 2016 Q2 | 169.2 Million KRW | -25.0% |
| 2016 Q3 | 169.2 Million KRW | 0.0% |
| 2016 FY | 169.2 Million KRW | -25.0% |
| 2016 Q4 | 169.2 Million KRW | 0.0% |
| 2016 Q1 | 225.6 Million KRW | 0.0% |
| 2015 Q1 | 282 Million KRW | 0.0% |
| 2015 Q3 | 225.6 Million KRW | 0.0% |
| 2015 Q2 | 225.6 Million KRW | -20.0% |
| 2015 Q4 | 225.6 Million KRW | 0.0% |
| 2015 FY | 225.6 Million KRW | -20.0% |
| 2014 FY | 282 Million KRW | -91.83% |
| 2014 Q4 | 282 Million KRW | 0.0% |
| 2014 Q3 | 282 Million KRW | 0.0% |
| 2014 Q1 | 2.93 Billion KRW | -15.03% |
| 2014 Q2 | 282 Million KRW | -90.39% |
| 2013 Q4 | 3.45 Billion KRW | -13.07% |
| 2013 FY | 3.45 Billion KRW | -38.18% |
| 2013 Q1 | 5.06 Billion KRW | -9.29% |
| 2013 Q2 | 4.49 Billion KRW | -11.36% |
| 2013 Q3 | 3.97 Billion KRW | -11.56% |
| 2012 Q2 | 6.62 Billion KRW | -7.99% |
| 2012 Q1 | 7.19 Billion KRW | -6.73% |
| 2012 Q3 | 6.1 Billion KRW | -7.84% |
| 2012 FY | 5.58 Billion KRW | -27.63% |
| 2012 Q4 | 5.58 Billion KRW | -8.5% |
| 2011 FY | 7.71 Billion KRW | 594.71% |
| 2011 Q4 | 7.71 Billion KRW | 95.39% |
| 2011 Q3 | 3.94 Billion KRW | 311.09% |
| 2011 Q2 | 960.83 Million KRW | 8.61% |
| 2011 Q1 | 884.68 Million KRW | -20.37% |
| 2010 Q1 | 1.84 Billion KRW | -10.92% |
| 2010 Q3 | 1.33 Billion KRW | -14.47% |
| 2010 Q4 | 1.11 Billion KRW | -16.92% |
| 2010 FY | 1.11 Billion KRW | -46.39% |
| 2010 Q2 | 1.56 Billion KRW | -15.31% |
| 2009 Q4 | 2.07 Billion KRW | 78.19% |
| 2009 FY | 2.07 Billion KRW | 267.43% |
| 2009 Q3 | 1.16 Billion KRW | 106.21% |
| 2009 Q2 | 564 Million KRW | 0.0% |
| 2009 Q1 | 564 Million KRW | 0.0% |
| 2008 Q1 | - KRW | 0.0% |
| 2008 Q2 | 282 Million KRW | 0.0% |
| 2008 Q3 | 564 Million KRW | 100.0% |
| 2008 Q4 | 564 Million KRW | 0.0% |
| 2008 FY | 564 Million KRW | 0.0% |
| 2007 Q2 | 4.74 Billion KRW | -4.55% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q1 | 4.97 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q3 | 4.71 Billion KRW | -0.64% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -330.509% |
| Yuhan Corporation | 60.23 Billion KRW | -15.27% |
| Yuhan Corporation | 60.23 Billion KRW | -15.27% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -409.025% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -409.025% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -409.025% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -132.393% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | -40.071% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 65.639% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -131.437% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -131.437% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -131.437% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -68091.601% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 3.718% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -274.85% |
| HANDOK Inc. | 123.78 Billion KRW | 43.908% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -561.249% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -14494.268% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 11.581% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | -116.972% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -57914.797% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | -100.815% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | -71.954% |
| Boryung Corporation | 151.7 Billion KRW | 54.234% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -11857.573% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -1566.359% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -1047.623% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -1047.623% |
| Suheung Co., Ltd. | 74 Billion KRW | 6.183% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -264.896% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -11661.833% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -22511.879% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -451.733% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -31609.382% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -31609.382% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -533.352% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 25.675% |
| JW Holdings Corporation | 20.65 Billion KRW | -236.109% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 42.619% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 15.357% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 57.139% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | -131.437% |
| JW Lifescience Corporation | 168 Million KRW | -41228.084% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -368.333% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -1459.549% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -4242.581% |